HPV16-specific immune characteristics in HPV vaccinees, patients with cervical precancerous lesions or cervical cancer
10.3760/cma.j.cn112866-20210324-00053
- VernacularTitle:HPV疫苗接种者与宫颈癌前病变及宫颈癌患者的HPV16特异性免疫特征
- Author:
Xiaowen HUANG
1
;
Can YUE
;
Xingxian SHI
;
Yingze ZHAO
;
Min MIN
;
Liqun YU
;
Peipei LIU
;
J. William LIU
;
Guolan GAO
Author Information
1. 中国科学院大学存济医学院，北京 100049
- Keywords:
HPV;
Vaccine;
Cytokines;
IgG antibody;
Cellular immunity
- From:
Chinese Journal of Experimental and Clinical Virology
2021;35(3):246-251
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To comparative investigate the HPV16 virus-specific immune characteristics of HPV vaccinees, cervical precancerous lesions patients and cervical cancer patients.Methods:Six female HPV vaccinees, five patients with cervical precancerous lesions or cervical cancer and 8 healthy female volunteers from Beijing were recruited as subjects. Peripheral anticoagulated blood specimens were collected from these subjects and the peripheral blood mononuclear cells (PBMCs) and plasma were isolated. After culturing in vitro with the stimulation of L1 protein peptide pool derived from HPV16 for 9-10 days, the percentage of CD4 + and CD8 + -T lymphocytes secreting cytokines IFN-γ, IL-2 and TNF-α in the PBMCs were detected by flow cytometry. The level of HPV16 IgG antibody in plasma was determined by ELISA. Results:The IgG levels of vaccinees were significantly higher than those of healthy donors as well as patients with cervical precancerous lesions or cervical cancer. Moreover, the specific CD4 + T cell immune level of vaccinees against HPV16 was significantly higher than that of healthy controls. Furthermore, there was a positive correlation between the level of specific T cell immunity and the level of antibody against HPV16 in all the donors (Pearson, r>0.4, p<0.05). Conclusions:The virus-specific immune responses, i. e. humoral responses as well as cellular immune responses are presenting diversely among different HPV-related subjects. HPV vaccinees possess robust humoral immunity and CD4 + T cell responses.
